EIDX - Eidos Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
0
0
0
0
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
37,738
28,539
9,286
1,734
Selling General and Administrative
11,333
9,240
2,730
651
Total Operating Expenses
49,071
37,779
12,016
2,385
Operating Income or Loss
-49,071
-37,779
-12,016
-2,385
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-4,619
-2,946
75
-157
Income Before Tax
-53,690
-40,725
-11,941
-2,542
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-53,690
-40,725
-11,941
-2,542
Net Income
-53,690
-40,725
-11,941
-2,542
Net Income available to common shareholders
-47,167
-40,725
-11,941
-2,542
Reported EPS
Basic
-
-1.86
-0.93
-0.13
Diluted
-
-1.86
-0.93
-0.13
Weighted average shares outstanding
Basic
-
21,367
12,777
19,575
Diluted
-
21,367
12,777
19,575
EBITDA
-
-37,779
-12,012
-2,385